Intra Cellular Therapies reported $868.58M in Assets for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Assets Change
Acadia Pharmaceuticals ACAD:US $ 624.25M 75.87M
ALKERMES ALKS:US $ 1977.84M 46.64M
Aptinyx Inc APTX:US $ 106.65M 8.27M
Biocryst Pharmaceuticals BCRX:US $ 527.72M 60.43M
Biogen BIIB:US $ 23614.4M 262.9M
Bristol Myers Squibb BMY:US $ 103034M 6280M
Cytokinetics CYTK:US $ 856.25M 14.93M
Esperion Therapeutics ESPR:US $ 342.85M 38.74M
Gilead Sciences GILD:US $ 63080M 4872M
Halozyme Therapeutics HALO:US $ 1162.25M 57.82M
Intra Cellular Therapies ITCI:US $ 868.58M 378.66M
JAZZ PHA JAZZ:US $ 11768.92M 529.72M
Johnson & Johnson JNJ:US $ 178355M 3663M
Marinus Pharmaceuticals MRNS:US $ 140.81M 3.97M
Minerva Neurosciences NERV:US $ 70.62M 6.5M
Nektar Therapeutics NKTR:US $ 1024.12M 93.07M
Novartis NVS:US $ 125218M 6577M
Prothena PRTA:US $ 581.41M 27.95M
Redhill Biopharma RDHL:US $ 167.05M 14.14M
Supernus Pharmaceuticals SUPN:US $ 1639.52M 49.64M
United Therapeutics UTHR:US $ 5359.8M 190.7M
Vanda Pharmaceuticals VNDA:US $ 603.56M 9.77M